- Alternative title
-
Therapie des epithelialen Ovarialkarzinomrezidivs
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Treatment of Recurrent Epithelial Ovarian Cancer ; volume:80 ; number:12 ; year:2020 ; pages:1195-1204
Geburtshilfe und Frauenheilkunde ; 80, Heft 12 (2020), 1195-1204
- Contributor
-
Claussen, Carlota
Rody, Achim
Hanker, Lars
- DOI
-
10.1055/a-1128-0280
- URN
-
urn:nbn:de:101:1-2021021111111593732847
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Claussen, Carlota
- Rody, Achim
- Hanker, Lars
Other Objects (12)
Surgery for Recurrent Epithelial Ovarian Cancer
Assessment of the efficacy and safety of anlotinib for the treatment of recurrent epithelial ovarian cancer
Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer
The detection, treatment, and biology of epithelial ovarian cancer
Surgery in recurrent ovarian cancer
Platelet count as a biomarker for monitoring treatment response and disease recurrence in recurrent epithelial ovarian cancer
Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
PET-CT in recurrent ovarian cancer: impact on treatment planning
Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?
Epithelial Ovarian Cancer-Cancer Institute (WIA) Experience
Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review
Surgery for Recurrent Epithelial Ovarian Cancer
Assessment of the efficacy and safety of anlotinib for the treatment of recurrent epithelial ovarian cancer
Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer
The detection, treatment, and biology of epithelial ovarian cancer
Surgery in recurrent ovarian cancer
Platelet count as a biomarker for monitoring treatment response and disease recurrence in recurrent epithelial ovarian cancer
Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
PET-CT in recurrent ovarian cancer: impact on treatment planning
Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?
Epithelial Ovarian Cancer-Cancer Institute (WIA) Experience
Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review
Surgery for Recurrent Epithelial Ovarian Cancer
Assessment of the efficacy and safety of anlotinib for the treatment of recurrent epithelial ovarian cancer
Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer
The detection, treatment, and biology of epithelial ovarian cancer
Surgery in recurrent ovarian cancer
Platelet count as a biomarker for monitoring treatment response and disease recurrence in recurrent epithelial ovarian cancer
Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
PET-CT in recurrent ovarian cancer: impact on treatment planning
Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?
Epithelial Ovarian Cancer-Cancer Institute (WIA) Experience